New Phase 1 Zika vaccine trial meets primary endpoint
by Press Release from Outbreak News Today on (#43B5N)
Emergent BioSolutions Inc. and Valneva SE announced this week positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The highly purified inactivated vaccine candidate, VLA1601, met the study's primary endpoint showing a favorable safety profile in all doses and schedules tested. VLA1601 was also immunogenic in all treatment groups and induced ["]
The post New Phase 1 Zika vaccine trial meets primary endpoint appeared first on Outbreak News Today.